Boston Scientific Co. (NYSE:BSX) Expected to Post Q1 2025 Earnings of $0.65 Per Share

Posted by Defense World Staff on Sep 25th, 2023

Boston Scientific logo

Boston Scientific Co. (NYSE:BSX – Free Report) – Zacks Research boosted their Q1 2025 EPS estimates for shares of Boston Scientific in a note issued to investors on Friday, September 22nd. Zacks Research analyst U. Biswas now expects that the medical equipment provider will post earnings of $0.65 per share for the quarter, up from their prior forecast of $0.62. The consensus estimate for Boston Scientific’s current full-year earnings is $1.99 per share. Zacks Research also issued estimates for Boston Scientific’s FY2025 earnings at $2.50 EPS.

Boston Scientific (NYSE:BSX – Get Free Report) last announced its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $0.53 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.49 by $0.04. The company had revenue of $3.60 billion for the quarter, compared to analysts’ expectations of $3.50 billion. Boston Scientific had a net margin of 6.81% and a return on equity of 15.16%. Boston Scientific’s revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.44 EPS.

A number of other brokerages have also weighed in on BSX. Stifel Nicolaus boosted their target price on Boston Scientific from $58.00 to $60.00 and gave the stock a “buy” rating in a research report on Thursday. StockNews.com lowered Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, September 2nd. Barclays boosted their target price on Boston Scientific from $59.00 to $60.00 and gave the stock an “overweight” rating in a research report on Friday. Morgan Stanley assumed coverage on shares of Boston Scientific in a research report on Tuesday, May 30th. They set an “overweight” rating and a $58.00 price target for the company. Finally, CL King assumed coverage on shares of Boston Scientific in a research report on Friday, June 30th. They set a “buy” rating and a $64.00 price target for the company. Two investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Boston Scientific presently has a consensus rating of “Moderate Buy” and a consensus price target of $60.10.

Get Our Latest Stock Analysis on BSX

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $53.60 on Monday. Boston Scientific has a fifty-two week low of $37.74 and a fifty-two week high of $55.38. The business has a 50-day simple moving average of $52.35 and a two-hundred day simple moving average of $51.81. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.80 and a current ratio of 1.29. The firm has a market cap of $78.48 billion, a price-to-earnings ratio of 89.33, a price-to-earnings-growth ratio of 2.10 and a beta of 0.78.

Insider Activity at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 113,355 shares of the company’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $53.91, for a total value of $6,110,968.05. Following the completion of the transaction, the chief executive officer now directly owns 1,498,922 shares in the company, valued at approximately $80,806,885.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Boston Scientific news, CEO Michael F. Mahoney sold 113,355 shares of the company’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $53.91, for a total value of $6,110,968.05. Following the completion of the transaction, the chief executive officer now directly owns 1,498,922 shares in the company, valued at approximately $80,806,885.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Wendy Carruthers sold 11,671 shares of the company’s stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $51.30, for a total value of $598,722.30. Following the completion of the transaction, the executive vice president now owns 62,321 shares of the company’s stock, valued at $3,197,067.30. The disclosure for this sale can be found here. In the last ninety days, insiders sold 217,635 shares of company stock worth $11,566,176. 0.71% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Fiduciary Alliance LLC bought a new position in shares of Boston Scientific during the 2nd quarter valued at approximately $25,000. Householder Group Estate & Retirement Specialist LLC bought a new position in shares of Boston Scientific during the 1st quarter valued at approximately $26,000. Asset Dedication LLC boosted its position in shares of Boston Scientific by 109.5% during the 1st quarter. Asset Dedication LLC now owns 551 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 288 shares during the last quarter. BDO Wealth Advisors LLC boosted its position in shares of Boston Scientific by 209.4% during the 2nd quarter. BDO Wealth Advisors LLC now owns 594 shares of the medical equipment provider’s stock valued at $32,000 after acquiring an additional 402 shares during the last quarter. Finally, Nemes Rush Group LLC bought a new position in shares of Boston Scientific during the 2nd quarter valued at approximately $33,000. 89.11% of the stock is currently owned by institutional investors.

Boston Scientific Company Profile

(Get Free Report)

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems.